[DA 3177 a new synthetic spasmolytic agent in the management of spastic-dyskinetic conditions of the digestive tract. Double-blind controlled clinical trial].
D000293:Adolescent; D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005767:Gastrointestinal Diseases / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000008:administration & dosage / Q000627:therapeutic use*; D012602:Scopolamine Derivatives / Q000627:therapeutic use*; D014287:Trimebutine / Q000627:therapeutic use
D010276:Parasympatholytics; D012602:Scopolamine Derivatives; D014287:Trimebutine
Il DA 3177, nuovo spasmolitico di sintesi, nella terapia degli stati spastici e discinetici dell'apparato digerente. Studio clinico controllato doppio cieco.